Terns Pharmaceuticals

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$0
$0
$0
$0
Gross Profit
-108
EBITDA
-23,921
-27,427
-25,735
-24,733
EBIT
-24,029
-27,596
-25,949
-24,939
Net Income
-24,093
-23,908
-21,799
-21,945
Net Change In Cash
0
0
0
0
Free Cash Flow
-18,880
-24,440
-14,584
-16,455
Cash
145,966
139,023
161,439
270,136
Basic Shares
91,575
91,473
91,240
77,819

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$0
$0
$0
$1,000
Gross Profit
-881
-1,032
1,000
EBITDA
-87,697
-102,266
-60,997
-49,348
EBIT
-88,593
-102,558
-62,029
-49,860
Net Income
-88,853
-90,210
-60,345
-50,158
Net Change In Cash
0
0
0
1,000
Cost of Revenue
95,714
Free Cash Flow
-70,058
-67,442
-49,384
-42,167
Cash
161,439
79,926
143,235
47,699
Basic Shares
79,507
71,259
36,033
25,269

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.26
2025-03-31
-$0.26
2024-12-31
-$0.24